Clinical Trial Update: PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma [Phase 2]

View source ↗

Summary

PA3-17 is being evaluated in a Phase 2 trial for adults with CD7-positive relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• PA3-17

Snippet

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Conditions: CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | Phase 2 | Status: RECRUITING